Drug Pipeline

PRX-102 2 mg/kg every 4 weeks Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
2
Phase 3
2
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-23 NCT03614234
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult…		 Trial completed
2026-05-23 NCT03614234
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult…		 date change Completion moved earlier: 2026-06-30 -> 2026-04-13
Active Studies by Phase
Phase 2/3
2
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 2/3
NCT05710692 Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With… Fabry Disease Recruiting
NCT06328608 A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and… Fabry Disease Recruiting
Not specified
NCT07109375 Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a… Fabry Disease Not Yet Recruiting
Sponsors Running PRX-102 2 mg/kg every 4 weeks Trials
Chiesi Farmaceutici S.p.A. (2) Chiesi Italia (1)
Get alerts when PRX-102 2 mg/kg every 4 weeks trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free